Skip Navigation


Cardiovascular Research Advance Access first published online on October 20, 2009
This version [Corrected Proof] published online on November 21, 2009

Cardiovascular Research, doi:10.1093/cvr/cvp347
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplementary Data
Right arrow All Versions of this Article:
cvp347v2    most recent
cvp347v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Merched, A.
Right arrow Articles by Chan, L.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Merched, A.
Right arrow Articles by Chan, L.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2009. For permissions please email: journals.permissions@oxfordjournals.org.

β2 integrins modulate the initiation and progression of atherosclerosis in low-density lipoprotein receptor knockout mice

Aksam Merched1,2,*, Katherine Tollefson1 and Lawrence Chan1,3

1 Department of Molecular and Cellular Biology, Baylor College of Medicine, One Baylor Plaza, R630, Houston, TX 77030, USA
2 INSERM 828, Avenue Haut Leveque, Pessac, France
3 Department of Molecular and Cellular Biology and Medicine, Division of Diabetes, Endocrinology & Metabolism, St Luke's Episcopal Hospital, Houston, TX 77030, USA

* Corresponding author. Tel: +1 713 798 4999, Fax: +1 713 798 8764, Email: amerched{at}bcm.edu

Aims: β2 integrin-mediated adhesion is thought to be a key event in cardiovascular disease. However, results of clinical trials targeting these molecules have been disappointing. Here, we investigated the effect of inactivation of β2 integrins at different stages of atherosclerosis by timed bone marrow transplantation (BMT) of CD18–/– cells in low-density lipoprotein receptor knockout (LDLR–/–) mice.

Methods and results: Early BMT before fatty streak formation revealed a short-term protective effect of CD18 (34% atherosclerotic lesion reduction). Once fatty streak lesions had developed (5-week atherogenic diet) before BMT, β2 integrin expression did not affect lesion progression. However, after the establishment of more mature lesions (pre-feeding mice the atherogenic diet for 10 weeks), CD18+/+ BMT enhanced atherosclerosis (36%) lesion progression compared with CD18–/– BMT. Furthermore, β2 integrins modulated the capacity of isolated peritoneal macrophages to take up acetylated LDL and native LDL and to phagocytose apoptotic cells, possibly via CD18-dependent mitogen-activated protein kinase signalling. Gene expression profile of CD18–/– and CD18+/+ macrophages revealed significant differences in putative protective as well as atherogenic functions.

Conclusion: β2 integrin-mediated interaction between leucocytes and the vessel wall is a time-dependent and dynamic process. During the initiation phase, it protects against atherosclerotic lesion formation. However, with the evolution of the lesion and chronic exposure to dyslipidaemia, β2 integrins’ pro-atherogenic action becomes dominant, accelerating the atherosclerotic process.

KEYWORDS Atherosclerosis; Adhesion; Integrins; Inflammation; Mice


Time for primary review: 30 days


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.